Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer

Table 3 Summary of clinical outcome and immunological response

Patients	No. of vaccine	Clinical response*	PFS (days)	OS (days)	After vaccine	ISR** (Grade)	Peptide-specific CTL
							CDCA1	CDH3	KIF20A
1	16	SD	212	310	No	2	0	1+	1+
2	8	PD	53	134	No	1	2+	0	1+
3	18	SD	127	205	No	1	1+	2+	1+
4	19	SD	505	659	Yes	2	1+	0	1+
5	27	SD	225	290	No	2	1+	1+	3+
6	10	SD	101	101		1	1+	1+	0
7	13	PD	64	164	Yes	1	2+	1+	2+
8	24	PD	64	353	Yes	2	3+	3+	3+
9	25	PD	57	380	Yes	2	2+	3+	2+

ISSN: 1479-5876